NCT06908356

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Praxis Precision Medicines · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures

Detailed description

An open label clinical trial to evaluate the efficacy and safety of PRAX-628 in adult patients with focal onset or primary generalized tonic-clonic seizures who can attest to concurrently taking at least 1, but no more than 3 acceptable anti-seizure medications.

Conditions

• Focal Onset Seizure
• Primary Generalized Epilepsy

Interventions

Type	Name	Description
DRUG	30mg PRAX-628	Once daily oral

Timeline

• Start date: 2025-01-10
• Primary completion: 2025-07-01
• Completion: 2025-07-01
• First posted: 2025-04-03
• Last updated: 2025-04-03

Locations

11 sites across 3 countries: United States, Australia, Spain

Regulatory

• FDA-regulated drug study